Abstract
Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population. We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean +/- standard deviation age, 29.0 +/- 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a change in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics. At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 +/- 0.6; p < 0.001), mean pulmonary ...Continue Reading
References
Sep 1, 1991·Annals of Internal Medicine·G E D'AlonzoJ T Kernis
Apr 1, 1986·Arthritis and Rheumatism·A M StupiT A Medsger
Apr 16, 1998·Heart·T W HigenbottamS Akamine
Jul 11, 2003·Chest·Olivier SitbonLewis J Rubin
Jun 15, 2004·Journal of the American College of Cardiology·Robyn J BarstSean Gaine
Jan 12, 2005·The American Journal of Cardiology·Steven M KawutRobyn J Barst
Jan 29, 2005·International Journal of Cardiology·Michael A GatzoulisJ Simon R Gibbs
Feb 3, 2005·The European Respiratory Journal·V V McLaughlinL J Rubin
Jan 25, 2006·European Heart Journal·Steeve ProvencherGérald Simonneau
Jun 28, 2006·Circulation·Nazzareno GalièUNKNOWN Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators
Dec 1, 2006·Heart·M D'AltoR Calabrò
Jan 16, 2007·Respiratory Medicine·Hsao-Hsun HsuYung-Chie Lee
Apr 3, 2007·Chest·Zhi-Cheng JingYue-Jin Yang
Apr 17, 2007·International Journal of Cardiology·Melinda CarringtonSimon Stewart
Jul 20, 2007·Heart·Gerhard-Paul DillerMichael A Gatzoulis
Jul 31, 2007·International Journal of Cardiology·Michael A GatzoulisUNKNOWN BREATHE-5 Investigators
Dec 20, 2007·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Mugdha ThakurDavid B Matchar
May 21, 2008·The American Journal of Cardiology·Kelly M ChinFernando Torres
Oct 30, 2008·The Annals of Pharmacotherapy·Sandra L Hrometz, Kelly M Shields
Feb 12, 2009·The Journal of Rheumatology·Giuseppe CellaJawed Fareed
Citations
Dec 12, 2012·American Journal of Respiratory and Critical Care Medicine·Wen-Hui WuZhi-Cheng Jing
Dec 23, 2010·Future Cardiology·Nathan Dwyer, David Kilpatrick
Jun 16, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Geoff StrangeEli Gabbay
Feb 19, 2011·Chest·Rui ZhangZhi-Cheng Jing
Feb 2, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Myung H Park, Lewis J Rubin
Sep 20, 2015·American Heart Journal·Kishan S ParikhZainab Samad
Jan 5, 2014·Internal Medicine Journal·G StrangeA Keogh
Jun 22, 2016·Heart Asia·Chen WangJian-Guo He
Aug 11, 2016·Lung·Michael KuntzSuvitesh Luthra
Apr 8, 2016·Cardiology in Review·Cristel S HjortshøjLars Søndergaard
Jun 2, 2018·Basic & Clinical Pharmacology & Toxicology·Jonas PedersenDaniela Grimm
Apr 16, 2021·Expert Review of Cardiovascular Therapy·Ana Barradas-PiresKonstantinos Dimopoulos
Jul 29, 2021·Journal of Clinical Pharmacy and Therapeutics·Qinhua ZhaoZhuang Tian